Palatin Technologies Inc PTN shares are trading lower after the company released results for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle for dry eye disease (DED). MELODY-1 had two co-primary efficacy endpoints: one clinical…
#pl9643 #phase3 #ded #itt #carlspana #spana #n16288 #n18287 #n20288 #n32287
Continue reading...